Taran, T.
Novartis (Switzerland)
2 papers on CoChat
Most cited papers
- Verified
Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2
Piccart, M., Hortobagyi, G. N., Campone, M., Pritchard, K. I., Lebrun, F., Ito, Y., Noguchi, S., Perez, A., Rugo, H. S., Deleu, I., et al. (2014) · Annals of Oncology
Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies
Cited by 574
- Verified
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival
Slamon, D. J., Neven, P., Chia, S., Jerusalem, G., De Laurentiis, M., Im, S., Petrakova, K., Valeria Bianchi, G., Martín, M., Nusch, A., et al. (2021) · Annals of Oncology
Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies
Cited by 281
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free